 |
answer text |
<p>The National Institute for Health and Care Excellence (NICE) updated its guidance
on ‘Early and locally advanced breast cancer: diagnosis and management’ in July 2018.
The use of adjuvant bisphosphonates was one of the key areas that was covered in the
update. NICE’s updated recommendations can be found at the following link:</p><p>
</p><p><a href="https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#bisphosphonate-therapy"
target="_blank">https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#bisphosphonate-therapy</a></p><p>
</p><p>The guideline recommends bisphosphonates as adjuvant therapy for postmenopausal
women with node positive invasive breast cancer and for postmenopausal women with
node negative breast cancer.</p><p> </p><p>NICE also updated its guidance on the use
of bisphosphonates for treating osteoporosis in February 2018. The updated guidance
can be found at the following link:</p><p> </p><p><a href="https://www.nice.org.uk/guidance/ta464"
target="_blank">https://www.nice.org.uk/guidance/ta464</a></p><p> </p><p>NICE recommends
oral bisphosphonates for treating osteoporosis in adults if the person is eligible
for risk assessment and the 10 year probability of osteoporotic fragility fracture
is at least 1%.</p>
|
|
